phenotypic reversal
Recently Published Documents


TOTAL DOCUMENTS

15
(FIVE YEARS 4)

H-INDEX

4
(FIVE YEARS 1)

2021 ◽  
Author(s):  
Hegias Mira-Bontenbal ◽  
Beatrice Tan ◽  
Cristina Gontan ◽  
Sander Goossens ◽  
R.G. Boers ◽  
...  

AbstractRett Syndrome is a neurodevelopmental disorder in girls that is caused by heterozygous inactivation of the chromatin remodeler gene MECP2. Rett Syndrome may therefore be treated by reactivation of the wild type copy of MECP2 from the inactive X chromosome. Most studies that model Mecp2 reactivation have used mouse fibroblasts rather than neural cells, which would be critical for phenotypic reversal, and rely on fluorescent reporters that lack adequate sensitivity. Here, we present a mouse model system for monitoring Mecp2 reactivation that is more sensitive and versatile than any bioluminescent and fluorescent system currently available. The model consists of neural stem cells derived from female mice with a dual reporter system where MECP2 is fused to NanoLuciferase and TdTomato on the inactive X chromosome. We show by bioluminescence and fluorescence that Mecp2 is synergistically reactivated by 5-Aza treatment and Xist knockdown. As expected, other genes on the inactive X chromosome are also reactivated, the majority of which overlaps with genes reactivated early during reprogramming of mouse embryonic fibroblasts to iPSCs. Genetic and epigenetic features such as CpG density, SINE elements, distance to escapees and CTCF binding are consistent indicators of reactivation, whereas different higher order chromatin areas are either particularly prone or resistant to reactivation. Our MeCP2 reactivation monitoring system thereby suggests that genetic and epigenetic features on the inactive X chromosome affect reactivation of its genes, irrespective of cell type or procedure of reactivation.


Author(s):  
Daisuke Yamashita ◽  
Victoria L Flanary ◽  
Rachel B Munk ◽  
Kazuhiro Sonomura ◽  
Saya Ozaki ◽  
...  

SummaryThe rise in aging population worldwide is increasing death from cancer, including glioblastoma. Here, we explore the impact of brain aging on glioma tumorigenesis. We find that glioblastoma in older patients and older mice displayed reduced neuronal signaling, including a decline of NTRK-like family member 6 (SLITRK6), a receptor for neurotrophic factor BDNF. This reduction was linked to the systemic decline of nicotinamide adenine dinucleotide (NAD+) with aging, as old mice exposed to young blood via parabiosis or supplemented with the NAD+ precursor NMN (nicotinamide mononucleotide) reverted phenotypically to young-brain responses to glioma, with reactivated neuronal signaling and reduced death from tumor burden. Interestingly, the phenotypic reversal by NMN was largely absent in old mice undergoing parabiosis with BDNF+/- young mice and in BDNF+/- mice undergoing tumor challenge, supporting the notion that the lower NAD+-BDNF signaling in the aging brain aggravated glioma tumorigenesis. We propose that the aging-associated decline in brain NAD+ worsens glioma outcomes at least in part by decreasing neuronal/synaptic activity and increasing neuroinflammation.


2020 ◽  
Author(s):  
Phaniendra Alugoju ◽  
Supreet Saini

AbstractThe question of chance vs. determinism in dictating evolutionary trajectories has been a broad question of interest in the last few decades. This question has not been addressed in the context of reverse evolution. By reverse evolution, we mean a scenario where selection is reversed. In this work, we use evolution of multicellularity in S. cerevisiae as a model to answer this question. When selected for fast-settling variants, multicellularity rapidly evolves in the organism. On reversing selection, unicellularity evolves from the multicellular clusters. However, the dynamic trajectories of the two processes are completely different. The molecular determinants dictating the two adaptive processes are also distinct from each other. In this context, evolution is not reversed dynamically or at a molecular level. The phenotypic reversal, however, is driven by epistatic interactions in the genome. How epistatic interactions evolve in a genome and shape evolutionary trajectories remains largely unknown.


2015 ◽  
Vol 35 (2) ◽  
pp. 430-439 ◽  
Author(s):  
Michaela Dümmer ◽  
Christian Michalski ◽  
Christoph Forreiter ◽  
Paul Galland

2015 ◽  
Vol 22 (5) ◽  
pp. 777-792 ◽  
Author(s):  
Laura A Marlow ◽  
Ilah Bok ◽  
Robert C Smallridge ◽  
John A Copland

Anaplastic thyroid carcinoma is a highly aggressive undifferentiated carcinoma with a mortality rate near 100% due to an assortment of genomic abnormalities which impede the success of therapeutic options. Our laboratory has previously identified that RhoB upregulation serves as a novel molecular therapeutic target and agents upregulating RhoB combined with paclitaxel lead to antitumor synergy. Knowing that histone deacetylase 1 (HDAC1) transcriptionally suppresses RhoB, we sought to extend our findings to other HDACs and to identify the HDAC inhibitor (HDACi) that optimally synergize with paclitaxel. Here we identify HDAC6 as a newly discovered RhoB repressor. By using isoform selective HDAC inhibitors (HDACi) and shRNAs, we show that RhoB has divergent downstream signaling partners, which are dependent on the HDAC isoform that is inhibited. When RhoB upregulates only p21 (cyclin kinase inhibitor) using a class I HDACi (romidepsin), cells undergo cytostasis. When RhoB upregulates BIMEL using class II/(I) HDACi (belinostat or vorinostat), apoptosis occurs. Combinatorial synergy with paclitaxel is dependent upon RhoB and BIMEL while upregulation of RhoB and only p21 blocks synergy. This bifurcated regulation of the cell cycle by RhoB is novel and silencing either p21 or BIMEL turns the previously silenced pathway on, leading to phenotypic reversal. This study intimates that the combination of belinostat/vorinostat with paclitaxel may prove to be an effective therapeutic strategy via the novel observation that class II/(I) HDACi antagonize HDAC6-mediated suppression of RhoB and subsequent BIMEL, thereby promoting antitumor synergy. These overall observations may provide a mechanistic understanding of optimal therapeutic response.


2014 ◽  
Vol 2014 ◽  
pp. 1-21 ◽  
Author(s):  
Dibyendu Talukdar ◽  
Tulika Talukdar

ALathyrus sativusL. mutant isolated in ethylmethane sulfonate-treated M2progeny of mother variety BioL-212 and designated asrlfL-1was characterized by inwardly rolled-leaf and stem and bud fasciations. The mutant exhibited karyomorphological peculiarities in both mitosis and meiosis with origin of aneuploidy. The mitosis was vigorous with high frequency of divisional cells and their quick turnover presumably steered cell proliferations. Significant transcriptional upregulations of cysteine and glutathione synthesis and concomitant stimulations of glutathione-mediated antioxidant defense helpedrlfL-1mutant to maintain balanced reactive oxygen species (ROS) metabolisms, as deduced by ROS-imaging study. Glutathione synthesis was shut down in buthionine sulfoximine- (BSO-) treated mother plant and mutant, and leaf-rolling and stems/buds fasciations in the mutant were reversed, accompanied by normalization of mitotic cell division process. Antioxidant defense was downregulated under low glutathione-redox but cysteine-desulfurations and photorespiratory glycolate oxidase transcripts were markedly overexpressed, preventing cysteine overaccumulation but resulted in excess H2O2in BSO-treated mutant. This led to oxidative damage in proliferating cells, manifested by severe necrosis in rolled-leaf and fasciated stems. Results indicated vital role of glutathione in maintaining abnormal proliferations in plant organs, and its deficiency triggered phenotypic reversal through metabolic diversions of cysteine and concomitant cellular and metabolic modulations.


2008 ◽  
Vol 6 (9) ◽  
pp. 38
Author(s):  
J. Nevo ◽  
E. Mattila ◽  
T. Pellinen ◽  
D.L. Yamamoto ◽  
H. Sara ◽  
...  

1999 ◽  
Vol 96 (20) ◽  
pp. 11341-11345 ◽  
Author(s):  
D. A. Pearce ◽  
C. J. Carr ◽  
B. Das ◽  
F. Sherman

Sign in / Sign up

Export Citation Format

Share Document